Showing 1411-1420 of 9336 results for "".
- UCSF's HS PROGRESS Aims to Shed Light on Hidradenitis Suppurativahttps://practicaldermatology.com/news/ucsfs-hs-progress-aims-to-shed-light-on-hidradenitis-suppurativa/2462092/University of California-San Francisco (UCSF) is leading HS PROGRESS (Hidradenitis Suppurativa [HS] Prospective Observational Registry and bioSpecimen repoSitory), a multicenter, longitudinal study that aims to comprehensively characterize HS from clinical and biological perspectives. At present,…
- Almirall Seeks Proposals to Better Understand Key Pathological Mechanisms of Skin Diseaseshttps://practicaldermatology.com/news/almirall-seeks-proposals-to-better-understand-key-pathological-mechanisms-of-skin-diseases/2462090/Almirall S.A. is calling for proposals to better understand key pathological mechanisms of several skin diseases through AlmirallShare, its open innovation platform. Almirall’s objective through this call is to identify and explore, through collaboration with external partners, common pathological…
- Man Vs. Machine: AI May Be as Reliable as Doctors for Diagnosing Skin Cancerhttps://practicaldermatology.com/news/man-vs-machine-ai-may-be-as-reliable-as-doctors-for-diagnosing-skin-cancer/2462088/Skin cancer diagnoses using artificial intelligence (AI) are as reliable as those made by medical experts, but doctors are clearly superior when it came to treatment decisions. These are the main takeaways from research looking at AI applications under realistic clinical conditions in two skin ca…
- TREMFYA (Guselkumab) Improves PsO Symptoms Across All Skin Toneshttps://practicaldermatology.com/news/tremfya-guselkumab-improves-pso-symptoms-across-all-skin-tones/2462086/TREMFYA demonstrated significant skin clearance, rapid scalp psoriasis clearance and improvement in health-related quality of life outcomes in psoriasis patients across all skin tones, according to results from Cohort A of the VISIBLE trial. This study, which was presented at the 2023 Fall Clinic…
- VTAMA (Tapinarof) Cream, 1% Shows Efficacy in Patients With Intertriginous Plaque Psoriasishttps://practicaldermatology.com/news/vtama-tapinarof-cream-1/2462085/VTAMA (tapinarof) Cream, 1% performed well in intertriginous plaque psoriasis (iPsO), according to new Phase 4 data presented at the 43rd Annual Fall Clinical Dermatology Conference in Las Vegas. This Phase 4 study expands the body of data for VTAMA cream in adult plaque psoriasis. In the two 12-w…
- Sciton Adds 1064nm Wavelength to mJOULE Platformhttps://practicaldermatology.com/news/sciton-adds-1064nm-wavelength-to-mjoule-platform/2462081/Sciton Inc. is expanding their mJOULE system to include ClearV and ClearSilk to treat vascular lesions and skin discoloration. "The combination of 1064 in the ClearV and ClearSilk delivery systems with the narrowband 532+ BBL filter replaces the need for all other vascular lasers in your practice.…
- Study: Female Adult Acne Patients Face Stigmahttps://practicaldermatology.com/news/study-female-adult-acne-patients-face-stigma/2462073/Faces with acne are seen as less attractive, trustworthy, confident, successful, dominant and happy, and adult female acne has the strongest negative effect, according to research presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. The researchers…
- Delgocitinib Cream Soothes Moderate to Severe Chronic Hand Eczemahttps://practicaldermatology.com/news/delgocitinib-cream-soothes-moderate-to-severe-chronic-hand-eczema/2462071/Delgocitinib cream produced statistically significant improvements in both patient- and clinician-reported efficacy outcomes in adults with moderate to severe chronic hand eczema (CHE) compared to cream vehicle, according to results from the DELTA 2 trial presented at the European Academy of Dermat…
- Sotyktu Demonstrates Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque PsOhttps://practicaldermatology.com/news/sotyktu-demonstrates-durable-efficacy-and-consistent-safety-for-up-to-three-years-in-moderate-to-severe-plaque-pso/2462066/Bristol Myers Squibb’s Sotyktu (deucravacitinib) shows durable efficacy and consistent safety for up to three years in people with moderate-to-severe plaque psoriasis, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress in Berlin, Germany. Sotykt…
- Topical NFX-179 Inhibits MEK Activity, May Prevents SCChttps://practicaldermatology.com/news/topical-nfx-179-inhibits-mek-activity-may-prevents-scc/2462063/Topical NFX-179 may prevent the development of cutaneous squamous cell carcinoma in pre-clinical models, according to a new article published in Science Translational Medicine. “Our previous work showed that the canonical mitogen-activated protein kinase (MAPK) signaling pathway is important for t…